Is ADT alone appropriate for high risk prostate cancer patients without evidence of metastasis and limited life expectancy?  

Is there data to support this practice, which appears in the NCCN guidelines?



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at University of Virginia School of Medicine
I agree with Ron's response and would like to add ...
Sign in or Register to read more